PMID- 18505168
OWN - NLM
STAT- MEDLINE
DCOM- 20080630
LR  - 20220317
IS  - 1359-6535 (Print)
IS  - 1359-6535 (Linking)
VI  - 13
IP  - 2
DP  - 2008
TI  - A systematic review of T-cell epitopes in hepatitis B virus: identification, 
      genotypic variation and relevance to antiviral therapeutics.
PG  - 161-75
AB  - BACKGROUND: The immune response to hepatitis B virus (HBV) is important for both 
      viral control and disease pathogenesis. A detailed understanding of the 
      HBV-specific T-cell responses may potentially lead to novel therapeutic 
      strategies for HBV. METHODS: All English language journal articles (including 
      articles in press) up to October 2007 were retrieved using searches of MEDLINE, 
      EMBASE and the Cochrane Controlled Trial Registry. An extensive database of HBV 
      sequences (SeqHepB) and GenBank were used to assess the degree of sequence 
      variation in each epitope. The new standardized nomenclature for HBV amino acid 
      position number was applied to all previously defined epitopes. RESULTS: 
      Forty-four HBV-specific human leukocyte antigen (HLA) class I restricted and 32 
      HBV-specific HLA class II restricted epitopes have been defined and have been 
      identified in all HBV genes. The majority of HLA class I restricted epitopes have 
      been defined in HLA-A2-positive individuals in the setting of acute HBV 
      infection. There is significant sequence variation of these epitopes within and 
      between HBV genotypes. Newer HBV immunotherapeutics appear promising but are 
      still in early phases of development. CONCLUSIONS: Identification of HBV-specific 
      epitopes in non-HLA-A2-positive individuals and recognition of genotypic 
      variation across epitopes are important for the future development of novel 
      immunotherapeutic strategies for the management of chronic HBV infection.
FAU - Desmond, Christopher P
AU  - Desmond CP
AD  - Department of Gastroenterology, Alfred Hospital, Melbourne, Australia.
FAU - Bartholomeusz, Angeline
AU  - Bartholomeusz A
FAU - Gaudieri, Silvana
AU  - Gaudieri S
FAU - Revill, Peter A
AU  - Revill PA
FAU - Lewin, Sharon R
AU  - Lewin SR
LA  - eng
GR  - AI060449/AI/NIAID NIH HHS/United States
GR  - R21 AI055379-01 A1/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Antivir Ther
JT  - Antiviral therapy
JID - 9815705
RN  - 0 (Antiviral Agents)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Amino Acid Sequence
MH  - Antiviral Agents/*therapeutic use
MH  - *Epitopes, T-Lymphocyte/chemistry/genetics/immunology
MH  - *Genetic Variation
MH  - Genotype
MH  - HLA Antigens/chemistry/immunology/metabolism
MH  - Hepatitis B virus/classification/drug effects/genetics/*immunology
MH  - Hepatitis B, Chronic/*drug therapy/virology
MH  - Humans
MH  - Molecular Sequence Data
RF  - 150
EDAT- 2008/05/29 09:00
MHDA- 2008/07/01 09:00
CRDT- 2008/05/29 09:00
PHST- 2008/05/29 09:00 [pubmed]
PHST- 2008/07/01 09:00 [medline]
PHST- 2008/05/29 09:00 [entrez]
PST - ppublish
SO  - Antivir Ther. 2008;13(2):161-75.